Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 9, 2010, Pages 1908-1916

  Thanassoulas, Angelos ^a   Nomikos, Michail ^a   Theodoridou, Maria ^a   Yannoukakos, Drakoulis ^a   Mastellos, Dimitris ^a   Nounesis, George ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

Chemical unfolding; ITC binding experiments; Thermodynamic stability

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRIP1 PROTEIN; PHENYLALANINE; PHOSPHOPEPTIDE; SERINE; UNCLASSIFIED DRUG; VALINE; BARD1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

AMINO ACID SUBSTITUTION; ARTICLE; DENATURATION; ENTHALPY; ISOTHERMAL TITRATION CALORIMETRY; LOW TEMPERATURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; ROOM TEMPERATURE; THERMODYNAMICS; THERMOSTABILITY; CHEMISTRY; CIRCULAR DICHROISM; GENETICS; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE;

AMINO ACID MOTIFS; CIRCULAR DICHROISM; HUMANS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 77955097286     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2010.04.012     Document Type: Article

References (56)

1. Baer R., Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 2002, 12:86-91.
2. Hashizume R., Fukuda M., Maeda I., Nishikawa H., Oyake D., Yabuki Y., Ogata H., Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 2001, 276:14537-14540.
3. Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L., Yang M.C., Hwang L.Y., Bowcock A.M., Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 1996, 14:430-440.
4. Irminger-Finger I., Jefford C.E. Is there more to BARD1 than BRCA1?. Nat. Rev. Cancer 2006, 6:382-391.
5. Feki A., Jefford C.E., Durand P., Harb J., Lucas H., Krause K.H., Irminger-Finger I. BARD1 expression during spermatogenesis is associated with apoptosis and hormonally regulated. Biol. Reprod. 2004, 71:1614-1624.
6. Fabbro M., Schuechner S., Au W.W., Henderson B.R. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. Exp. Cell Res. 2004, 298:661-673.
7. Rodriguez J.A., Schuchner S., Au W.W., Fabbro M., Henderson B.R. Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1. Oncogene 2004, 23:1809-1820.
8. Fox D., Le Trong I., Rajagopal P., Brzovic P.S., Stenkamp R.E., Klevit R.E. Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences. J. Biol. Chem. 2008, 283:21179-21186.
9. Westermark U.K., Reyngold M., Olshen A.B., Baer R., Jasin M., Moynahan M.E. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol. Cell. Biol. 2003, 23:7926-7936.
10. McCarthy E.E., Celebi J.T., Baer R., Ludwig T. Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol. Cell. Biol. 2003, 23:5056-5063.
11. Joukov V., Chen J., Fox E.A., Green J.B., Livingston D.M. Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12078-12083.
12. Boulton S.J., Martin J.S., Polanowska J., Hill D.E., Gartner A., Vidal M. BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans. Curr. Biol. 2004, 14:33-39.
13. Reidt W., Wurz R., Wanieck K., Chu H.H., Puchta H. A homologue of the breast cancer-associated gene BARD1 is involved in DNA repair in plants. EMBO J. 2006, 25:4326-4337.
14. Irminger-Finger I., Leung W.C., Li J., Dubois-Dauphin M., Harb J., Feki A., Jefford C.E., Soriano J.V., Jaconi M., Montesano R., Krause K.H. Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol. Cell 2001, 8:1255-1266.
15. Tsuzuki M., Wu W., Nishikawa H., Hayami R., Oyake D., Yabuki Y., Fukuda M., Ohta T. A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats. Cancer Lett. 2006, 233:108-116.
16. Li L., Ryser S., Dizin E., Pils D., Krainer M., Jefford C.E., Bertoni F., Zeillinger R., Irminger-Finger I. Oncogenic BARD1 isoforms expressed in gynecological cancers. Cancer Res. 2007, 67:11876-11885.
17. Dizin E., Irminger-Finger I. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1. Int. J. Biochem. Cell Biol. 2010.
18. Irminger-Finger I. BARD1, a possible biomarker for breast and ovarian cancer. Gynecol. Oncol. 2009.
19. Sauer M.K., Andrulis I.L. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer. J. Med. Genet. 2005, 42:633-638.
20. Thai T.H., Du F., Tsan J.T., Jin Y., Phung A., Spillman M.A., Massa H.F., Muller C.Y., Ashfaq R., Mathis J.M., Miller D.S., Trask B.J., Baer R., Bowcock A.M. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum. Mol. Genet. 1998, 7:195-202.
21. De Brakeleer S., De Greve J., Loris R., Janin N., Lissens W., Sermijn E., Teugels E. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum. Mutat. 2010, 31:E1175-1185.
22. Manke I.A., Lowery D.M., Nguyen A., Yaffe M.B. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003, 302:636-639.
23. Williams R.S., Lee M.S., Hau D.D., Glover J.N. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat. Struct. Mol. Biol. 2004, 11:519-525.
24. Yu X., Chini C.C., He M., Mer G., Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003, 302:639-642.
25. Clapperton J.A., Manke I.A., Lowery D.M., Ho T., Haire L.F., Yaffe M.B., Smerdon S.J. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat. Struct. Mol. Biol. 2004, 11:512-518.
26. Shiozaki E.N., Gu L., Yan N., Shi Y. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol. Cell 2004, 14:405-412.
27. Varma A.K., Brown R.S., Birrane G., Ladias J.A. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. Biochemistry 2005, 44:10941-10946.
28. Shen Y., Tong L. Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1. Biochemistry 2008, 47:5767-5773.
29. Stucki M., Clapperton J.A., Mohammad D., Yaffe M.B., Smerdon S.J., Jackson S.P. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 2005, 123:1213-1226.
30. Birrane G., Varma A.K., Soni A., Ladias J.A. Crystal structure of the BARD1 BRCT domains. Biochemistry 2007, 46:7706-7712.
31. Rodriguez M., Yu X., Chen J., Songyang Z. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J. Biol. Chem. 2003, 278:52914-52918.
32. Nikolopoulos G., Pyrpassopoulos S., Thanassoulas A., Klimentzou P., Zikos C., Vlassi M., Vorgias C.E., Yannoukakos D., Nounesis G. Thermal unfolding of human BRCA1 BRCT-domain variants. Biochim. Biophys. Acta 2007, 1774:772-780.
33. Lakowicz J.R. Principles of fluorescence spectroscopy 2006, Springer, New York. 3rd ed.
34. Eftink M.R. Fluorescence techniques for studying protein structure. Meth. Biochem. Anal. 1991, 35:127-205.
35. Royer C.A. Fluorescence spectroscopy. Meth. Mol. Biol. 1995, 40:65-89.
36. Altekar W. Fluorescence of proteins in aqueous neutral salt solutions. I. Influence of anions. Biopolymers 1977, 16:341-368.
37. Eftink M.R. Fluorescence methods for studying equilibrium macromolecule-ligand interactions. Meth. Enzymol. 1997, 278:221-257.
38. Eftink M.R., Shastry M.C. Fluorescence methods for studying kinetics of protein-folding reactions. Meth. Enzymol. 1997, 278:258-286.
39. Plotnikov V.V., Brandts J.M., Lin L.N., Brandts J.F. A new ultrasensitive scanning calorimeter. Anal. Biochem. 1997, 250:237-244.
40. Wiseman T., Williston S., Brandts J.F., Lin L.N. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 1989, 179:131-137.
41. Clarke J., Fersht A.R. Engineered disulfide bonds as probes of the folding pathway of barnase: increasing the stability of proteins against the rate of denaturation. Biochemistry 1993, 32:4322-4329.
42. Fersht A. Structure and mechanism in protein science: a guide to enzyme catalysis and protein folding 1999, W.H. Freeman, New York.
43. Ekblad C.M., Wilkinson H.R., Schymkowitz J.W., Rousseau F., Freund S.M., Itzhaki L.S. Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1. J. Mol. Biol. 2002, 320:431-442.
44. Edwards R.A., Lee M.S., Tsutakawa S.E., Williams R.S., Nazeer I., Kleiman F.E., Tainer J.A., Glover J.N. The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50. Biochemistry 2008, 47:11446-11456.
45. Pyrpassopoulos S., Ladopoulou A., Vlassi M., Papanikolau Y., Vorgias C.E., Yannoukakos D., Nounesis G. Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1. Biophys. Chem. 2005, 114:1-12.
46. Woody R.W. Circular dichroism. Meth. Enzymol. 1995, 246:34-71.
47. Li M.S., Klimov D.K., Thirumalai D. Finite size effects on thermal denaturation of globular proteins. Phys. Rev. Lett. 2004, 93:268107.
48. Ekblad C.M., Friedler A., Veprintsev D., Weinberg R.L., Itzhaki L.S. Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis. Protein Sci. 2004, 13:617-625.
49. Williams R.S., Green R., Glover J.N. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat. Struct. Biol. 2001, 8:838-842.
50. Lee M.S., Edwards R.A., Thede G.L., Glover J.N. Structure of the BRCT repeat domain of MDC1 and its specificity for the free COOH-terminal end of the gamma-H2AX histone tail. J. Biol. Chem. 2005, 280:32053-32056.
51. Campbell S.J., Edwards R.A., Glover J.N. Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1. Structure 2010, 18:167-176.
52. Nomine Y., Botuyan M.V., Bajzer Z., Owen W.G., Caride A.J., Wasielewski E., Mer G. Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations. Biochemistry 2008, 47:9866-9879.
53. Bas D.C., Rogers D.M., Jensen J.H. Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins 2008, 73:765-783.
54. Li H., Robertson A.D., Jensen J.H. Very fast empirical prediction and rationalization of protein pKa values. Proteins 2005, 61:704-721.
55. Edgcomb S.P., Murphy K.P. Variability in the pKa of histidine side-chains correlates with burial within proteins. Proteins 2002, 49:1-6.
56. Laufer M., Nandula S.V., Modi A.P., Wang S., Jasin M., Murty V.V., Ludwig T., Baer R. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair. J. Biol. Chem. 2007, 282:34325-34333.